Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

39

Revenue 2017

Orencia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Orencia was produced by Bristol-Myers Squibb.

BMS shares fall on nivolumab jitters despite solid Q4 results

BMS shares fall on nivolumab jitters despite solid Q4 results Away from oncology, arthritis treatment Orencia (abatacept) rose 22 per cent to $397m despite an increasingly crowded market and with a new subcutaneous formulation driving growth, while hepatitis B treatment Baraclude

BMS exits hep C, diabetes and neuroscience drug discovery

BMS exits hep C, diabetes and neuroscience drug discovery But it pledged to continue to advance its oral anticoagulant Eliquis (apixaban); cancer drugs Sprycel (dasatinib) and Erbitux (cetuximab); Orencia (abatacept) for arthritis; hepatitis B treatment Baraclude (entecavir); and HIV drugs

Positive data for BMS’ clazakizumab in arthritis

Positive data for BMS’ clazakizumab in arthritis If it reaches market the drug will slot into the company's RA portfolio alongside anti-CD80 antibody Orencia (abatacept), which brought in a little over $1bn in the first nine

BMS bounces back to form in Q3

BMS bounces back to form in Q3 Orencia (abatacept) for rheumatoid arthritis which rose 22 per cent to $307m.

BMS signs 10-year biologic manufacturing deal with Samsung

BMS signs 10-year biologic manufacturing deal with Samsung Earlier this year BMS outlined its plans for a major expansion of a US plant for its rheumatoid arthritis biologic Orencia (abatacept), which was launched in Europe in 2010, but will

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...